Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The results of the AURORA 1 study show a superior effect on renal remission for voclosporin plus standard care over standard care alone in patients with lupus nephritis.
Targeting DNA methylation using a repurposed cancer drug reduces joint damage in mouse models of autoimmune arthritis by restoring the balance between T cell subsets.
A paper in JCI Insight reports a role for antibody glycosylation in the pathogenesis of lupus nephritis and suggests CaMK4 as a potential urinary biomarker of active disease.
Two new studies have identified mutations in UBA1 associated with the newly identified condition VEXAS syndrome in cohorts of patients with relapsing polychondritis, supporting the concept that relapsing polychondritis is more than one disease.
New research suggests that advanced inflammatory arthritis could be treated with a targeted chemotherapeutic strategy to selectively induce apoptosis in osteoclasts and inflammatory macrophages in affected joints.
Preclinical research suggests that inhibitors of PIM kinases currently in development in oncology could be repurposed for the treatment of early rheumatoid arthritis.
The Systemic Lupus International Collaborating Clinics–ACR Damage Index (SDI) has been widely used for 25 years. This index, however, has its limitations, providing a rationale for a global initiative to create a revised, updated SDI to capture organ damage across the age-spectrum.